CANTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Organogenesis Inc., a global leader in advanced wound care innovations and technologies, today announced that its PuraPly™ and PuraPly Antimicrobial (AM)™ wound management products are now eligible ...
CANTON, Mass., March 15, 2018 /PRNewswire/ -- Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the ...
Starting January 1, 2017, both PuraPly and PuraPly Antimicrobial (AM) will be billed as Q-code Q4172 under the Healthcare Common Procedure Coding System (HCPCS). This change will expand coverage to ...
Statistically significant (p<0.0477) DFU wound closure at 12 weeks RCT compared PuraPly®AM plus standard of care to standard of care alone Results strengthen existing clinical evidence supporting ...
CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for ...
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE)-- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results